Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.88 |
| ▸ | FLT3 | P36888 | 2/20 | 0.79 |
| ▸ | KIT | P10721 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 4/20 | 0.75 |
| ▸ | TEC | P42680 | 3/20 | 0.75 |
| ▸ | BMX | P51813 | 3/20 | 0.75 |
| ▸ | ITK | Q08881 | 3/20 | 0.75 |
| ▸ | TXK | P42681 | 2/20 | 0.75 |
| ▸ | LYN | P07948 | 2/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.75 |
| ▸ | BLK | P51451 | 2/20 | 0.75 |
| ▸ | LCK | P06239 | 2/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.75 |
| ▸ | LATS1 | O95835 | 1/20 | 0.75 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.75 |
| ▸ | FYN | P06241 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613911 | 1.00 | BTK (0.88) | BTKFLT3KITEGFRTEC | |
| SCHEMBL17951884 | 0.94 | BTK (0.89) | BTKFLT3KITEGFRTEC | |
| SCHEMBL30797832 | 0.94 | BTK (1.00) | BTKFLT3KITEGFRTEC | |
| SCHEMBL3363036 | 0.93 | BTK (0.85) | BTKFLT3KITEGFRTEC | |
| SCHEMBL22625356 | 0.93 | BTK (0.85) | BTKFLT3KITEGFRTEC | |
| SCHEMBL31615786 | 0.93 | BTK (0.85) | BTKFLT3KITEGFRTEC | |
| SCHEMBL20204786 | 0.93 | BTK (0.85) | BTKFLT3KITEGFRTEC | |
| SCHEMBL17951807 | 0.92 | BTK (0.84) | BTKFLT3KITEGFRTEC | |
| SCHEMBL22625353 | 0.92 | BTK (0.84) | BTKFLT3KITEGFRTEC | |
| SCHEMBL19649286 | 0.92 | BTK (0.84) | BTKFLT3KITEGFRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116023397-A | Preparation method of ibrutinib dimer impurity | 深圳振强生物技术有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-116023397-A | Preparation method of ibrutinib dimer impurity | 深圳振强生物技术有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-116023397-A | Preparation method of ibrutinib dimer impurity | 深圳振强生物技术有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-115716832-A | Preparation method and application of ibrutinib impurity | 深圳鼎邦化学品有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20220204516-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-30 | — | — | US | disclosed |
| CN-109206426-B | Process for preparing pyrazolopyrimidines | 上海复星星泰医药科技有限公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3248979-B1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INST PHYSICAL SCI CAS (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-20200347064-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-23 | — | — | US | disclosed |
| EP-3201197-B1 | ACID ADDITION SALT OF IBRUTINIB | RATIOPHARM GMBH (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-9012463-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2650294-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650294-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2011046964-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204516-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR | BTK, SYK, LYN | BTK 1/4885FLT3 8/4885KIT 1046/4885 |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885FLT3 139/4885KIT 692/4885 |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885FLT3 139/4885KIT 692/4885 |
| US-20200347064-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | BTK 1/4885FLT3 27/4885KIT 1389/4885 |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | BTK 35/4885FLT3 1/4885KIT 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.